Alex Therapeutics AB
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Alex Therapeutics AB - overview
Established
2018
Location
Stockholm, -, Sweden
Primary Industry
Healthcare IT
About
Based in Stockholm, Sweden, and founded in 2018 by John Drakenberg Renander (CEO) and Oliver Fleetwood, Alex Therapeutics AB, aka Alex Therapeutics, is a firm that operates as a provider of a platform that allows easy development of digital therapeutics treatment products. The business has enabled more than $1. 4 trillion in underwritten loans since its establishment. In April 2022, Alex Therapeutics AB raised SEK 36.
2 million in venture funding led by new investor Hadean Ventures, with participation from other new investors Scale Capital and Bonit Capital. The firm offers a digital therapeutics (DTx) products development platform that includes AI-engine, CBT modules, design system, regulatory framework. The product offerings include Alex – quit smoking which is presently accessible in 150 countries worldwide through Apple App Store and Google Play. There are also certain products that are in the developing stage.
The business intends to use the funds raised in 2022 for expanding its business in Europe and the U. S. and evolving new digital therapeutics by partnering with pharma firms.
Current Investors
Sweet Studio, Scale Capital, Hadean Ventures
Primary Industry
Healthcare IT
Sub Industries
Healthcare, Healthcare IT, Software
Website
www.alextherapeutics.com
Verticals
HealthTech, Manufacturing, Mobile Apps
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Alex Therapeutics AB - timeline of key events
Alex Therapeutics AB - financials
| Fiscal Year Ended | Aug 31, 2018 | Aug 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | 1,100,004 | 3,780,715 | 6,636,173 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - |
| EBITDA (USD) | (217,211) | (1,063,306) | (148,554) | 995,746 | - | - | - |
| Operating Income (USD) | (217,211) | (1,063,306) | (148,554) | 990,513 | - | - | - |
| Operating Margin | - | (96.7%) | (3.9%) | 14.9% | - | - | - |
| % EBITDA Margin | - | (96.7%) | (3.9%) | 15.0% | - | - | - |
| NET Income (USD) | (217,203) | (1,121,008) | (148,810) | 993,669 | - | - | - |
| % Net Margin | - | (101.9%) | (3.9%) | 15.0% | - | - | - |
Alex Therapeutics AB - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.